Polyplus-transfection Sa
STRASBOURG, France, September 16, 2011 -
Polyplus-transfection celebrates 10 years of commercial growth and research and development in the field of transfection bio-tools and therapeutics with further additions to team
Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates 10 years of continuous growth.
STRASBOURG, France, May 11, 2011 - Polyplus-transfection SA, a privately-held company developing innovative
technologies for molecular and cellular biology, announced today that
ExcellGene SA, a privately held company providing rapid and low-cost
solutions for protein manufacturing and process development based on
mammalian cells to the Pharma/Biotech industry, has signed an extended supply
agreement for Polyplus-transfection polyethylenimine (PEI) based transfection
reagents.
STRASBOURG, France, March 29, 2011 - Polyplus-transfection SA, a privately-held company developing innovative
solutions for the delivery of nucleic acids in research, bioproduction and
therapy, announced today that it has granted Roche Glycart AG, a Swiss
biotechnology company fully-owned by Roche, a non exclusive license to use
polyethylenimine (PEI) for in vitro transfection applications for research
purposes.
STRASBOURG, France, March 16, 2011 - Polyplus-transfection SA, which specializes in the development
of innovative solutions for the delivery of nucleic acids in research and
therapeutics, announces the completion of a funding round in which it raised
EUR 2.5 million.
